Retrieved on:
Wednesday, January 17, 2024
WARRINGTON, Pa., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced it has entered into a license agreement with Lee’s Pharmaceutical (HK) Limited (“Lee’s”) for the development and commercialization of Windtree’s product candidate istaroxime in Greater China, including for acute heart failure and cardiogenic shock. In addition to istaroxime, the agreement also licenses Windtree’s preclinical next-generation SERCA2a activators, known as dual mechanism SERCA2a activators, and rostafuroxin, a Phase 2 product candidate for hypertension associated with specific genotypes.
Key Points:
- In addition to istaroxime, the agreement also licenses Windtree’s preclinical next-generation SERCA2a activators, known as dual mechanism SERCA2a activators, and rostafuroxin, a Phase 2 product candidate for hypertension associated with specific genotypes.
- “We believe Windtree’s pipeline has great potential and we expect this license agreement will progress development in the treatment of heart failure.
- Windtree already studied istaroxime in heart failure patients in China and the results of the Company’s positive Phase 2b study have been presented and published.
- Lee’s will be responsible for funding all development, manufacturing, regulatory and commercial costs for the covered products in the licensed region.
Retrieved on:
Thursday, November 16, 2023
European Patent Office,
Therapy,
Ageing,
Windtree Therapeutics,
Heart,
Patient,
Heart failure,
European Patent Convention,
Diagnosis,
Patent,
Family,
Hospital,
PURE,
Pharmaceutical industry 3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates.
Key Points:
- 3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates.
- The pure SERCA2a Activators are one of two families of preclinical drug candidates that act on SERCA2a in the Company’s pipeline.
- The new European patent, titled: “ANDROSTANE DERIVATIVES WITH ACTIVITY AS PURE OR PREDOMINANTLY PURE STIMULATORS OF SERCA2A FOR THE TREATMENT OF Heart Failure,” provides patent protection until October 9, 2039 for the family of compounds with the pure SERCA2a mechanism of action.
- Windtree believes activation of SERCA2a represents a potentially important advancement in heart failure treatment for patients,” said Craig Fraser, CEO of Windtree Therapeutics.
Retrieved on:
Wednesday, August 23, 2023
Patent,
Acute decompensated heart failure,
IV,
Heart failure,
Cardiogenic shock,
Windtree Therapeutics,
HEART,
Heart,
European Patent Office,
LIKE,
European Patent Convention,
Therapy,
Pharmaceutical industry The new composition of matter patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection through late 2039.
Key Points:
- The new composition of matter patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection through late 2039.
- The newly issued patent follows the Company’s announcement in April 2023 that the European Patent Office granted Patent No.
- 3599243, which also provides patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
- Istaroxime and these follow-on SERCA2a Activators look to deliver on the potential of SERCA2a activation in heart failure.
Patent,
Acute decompensated heart failure,
Cardiogenic shock,
IV,
Windtree Therapeutics,
HEART,
Heart,
European Patent Office,
IP,
LIKE,
European Patent Convention,
Therapy,
Pharmaceutical industry A notice of allowance is issued by the USPTO to indicate that the application has passed examination.
Key Points:
- A notice of allowance is issued by the USPTO to indicate that the application has passed examination.
- The Company previously reported that the European Patent Office granted Patent No.
- 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
- Windtree has preclinical drug candidates with dual mechanisms of action (inhibition of the Na+/K+ pump and activation of SERCA2a) as well as pure SERCA2a activators (devoid of action on the Na+/K+ pump).
Patent,
Acute decompensated heart failure,
IV,
Cardiogenic shock,
Heart failure,
Windtree Therapeutics,
HEART,
Heart,
Opposition procedure before the European Patent Office,
LIKE,
Patient,
European Patent Convention,
Therapy,
Family,
Pharmaceutical industry 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
Key Points:
- 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
- The new patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection until July 2038 for the family of compounds with a dual mechanism of action.
- Windtree believes therapies that activate SERCA2a represent a potential important advancement in heart failure treatment for patients,” said Craig Fraser, CEO and President of Windtree Therapeutics.
- Compounds that activate SERCA2a have been aggressively pursued as much sought-after targets in the treatment of heart failure, and Windtree has found a unique mechanism that activates SERCA2a.”
